Itriglumide

Drug Profile

Itriglumide

Alternative Names: CR-2945

Latest Information Update: 11 Apr 2016

Price : $50

At a glance

  • Originator Rottapharm
  • Developer Rottapharm Madaus
  • Class Antiulcers; Anxiolytics
  • Mechanism of Action Cholecystokinin B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Anxiety disorders; Gastrointestinal cancer; Gastrointestinal disorders
  • Discontinued Sleep apnoea syndrome

Most Recent Events

  • 11 Apr 2016 Rottapharm completes a phase II trial for Sleep apnoea syndrome in Italy (EudraCT2013-004469-15) prior to April 2016
  • 15 Oct 2015 Discontinued - Phase-II for Sleep apnoea syndrome (Treatment-naive) in Italy (PO)
  • 17 Aug 2015 No recent reports on development identified - Phase-II for Anxiety disorders, Gastrointestinal cancer, and Gastrointestinal disorders in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top